A multi-targeted approach to treating bone metastases

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 545-553

  Camacho, Daniel F ^a   Pienta, Kenneth J ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone metastasis; Ecotherapy; Microenvironment; Prostate cancer; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BONE MATRIX; BONE NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MATRIX; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY; MALE; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84905118291     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9476-y     Document Type: Article

References (91)

1. Li, S., Peng, Y., Weinhandl, E. D., Blaes, A. H., Cetin, K., & Chia, V. M., et al. (2012). Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol, 4, 87-93.
2. Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007). The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA: A Cancer Journal for Clinicians, 57(4), 225-241. (Pubitemid 47312082)
3. Fidler, I. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews. Cancer, 3, 1-6.
4. Paget, S. (1889). The distribution of secondary growth in cancer of breast. Lancet, 1, 98-101.
5. Ewing, J. (1919). Metastasis. In Neoplastic diseases (pp. 76-88). Philadelphia: Saunders.
6. Pienta, K. J., & Loberg, R. (2005). The 'emigration, migration, and immigration' of prostate cancer. Clinical Prostate Cancer, 4(1), 24-30. (Pubitemid 41018179)
7. Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Research, 48, 7067-7071.
8. Zetter, B. (1998). Angiogenesis and tumormetastasis. Annual Review of Medicine, 49, 407-424.
9. Wang, J., Loberg, R., & Taichman, R. S. (2006). The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Reviews, 25(4), 573-587. (Pubitemid 46071864)
10. Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T., & Gronthos, S. (2005). Stromal-derived factor-1 promotes the growth, survival, and development of human bonemarrow stromal stemcells. Blood, 105(10), 3793-3801. (Pubitemid 40656121)
11. Jung, Y., Wang, J., Schneider, A., Sun, Y.-X., Koh-Paige, A. J., Osman, N. I., et al. (2006). Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone, 38(4), 497-508.
12. Sun, Y., Fang, M., Wang, J., Cooper, C. R., Pienta, K. J., & Taichman, R. S., et al. (2007). Expression and Activation of a v b 3 Integrins by SDF-1 / CXC12 Increases the Aggressiveness of Prostate Cancer Cells. Prostate, 67(1), 61-73. (Pubitemid 46013468)
13. Sun, Y.-X., Schneider, A., Jung, Y., Wang, J., Dai, J., Wang, J., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 20(2), 318-329.
14. Havens, A. M., Jung, Y., Sun, Y. X., Wang, J., Shah, R., Bühring, H., et al. (2006). The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC cancer, 6, 195.
15. Jung, Y., Wang, J., Song, J., Shiozawa, Y., Wang, J., Havens, A., et al. (2007). Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 110(1), 82-90. (Pubitemid 47026822)
16. Sikes, R. A., Nicholson, B. E., Koeneman, K. S., Edlund, N. M., Bissonette, E. A., Bradley, M. J., et al. (2004). Cellular interactions in the tropism of prostate cancer to bone. International Journal of Cancer, 110(4), 497-503. (Pubitemid 38658014)
17. Chung, L. W. K., Baseman, A., Assikis, V., & Zhau, H. E. (2005). Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. The Journal of Urology, 173, 10-20. (Pubitemid 39627663)
18. Lipton, A. (2006). Future treatment of bone metastases. Clinical Cancer Research, 12(20 Pt 2), 6305s-6308s.
19. Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature reviews. Cancer, 2(8), 584-593.
20. Loberg, R. D., Logothetis, C. J., Keller, E. T., & Pienta, K. J. (2005). Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(32), 8232-8241.
21. Candelaria-Quintana, D., Dayao, Z. R., & Royce, M. E. (2012). The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer. Breast cancer research and treatment, 132(2), 355-363.
22. Fornier, M. N. (2010). Denosumab: second chapter in controlling bone metastases or a new book? Journal of Clinical Oncology, 28(35), 5127-5131.
23. Ha, T. C., & Li, H. (2007). Meta-analysis of clodronate and breast cancer survival. British Journal of Cancer, 96(12), 1796-1801. (Pubitemid 46912011)
24. Wu, S., Dahut, W. L., & Gulley, J. L. (2007). The use of bisphosphonates in cancer patients. Acta Oncologica, 46(5), 581-591. (Pubitemid 46911914)
25. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879-882. (Pubitemid 38807610)
26. Lüftner, D., Henschke, P., & Possinger, K. (2007). Clinical value of bisphosphonates in cancer therapy. Anticancer research, 27(4A), 1759-1768. (Pubitemid 46954673)
27. Schwarz, E. M., & Ritchlin, C. T. (2007). Clinical development of anti-RANKL therapy. Arthritis Research & Therapy, 9(Suppl 1), S7.
28. Tsourdi, E., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011). Denosumab for bone diseases: translating bone biology into targeted therapy. European Journal of Endocrinology, 165(6), 833-840.
29. Miyazaki, T., Tanaka, S., Sanjay, A., & Baron, R. (2006). The role of c-Src kinase in the regulation of osteoclast function. Modern Rheumatology, 16(2), 68-74.
30. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., et al. (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer research, 67(5), 2226-2238. (Pubitemid 46424242)
31. Vandyke, K., Dewar, A. L., Diamond, P., Fitter, S., Schultz, C. G., Sims, N. A., et al. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770.
32. Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., & Fitzpatrick, L. A. (1997). The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis : implications for the development of metastatic disease. Endocrinology, 138(3), 1145-1150. (Pubitemid 27089772)
33. Zangari, M., Esseltine, D., Lee, C.-K., Barlogie, B., Elice, F., Burns, M. J., et al. (2005). Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 131, 71-73. (Pubitemid 43899710)
34. Terpos, E., Heath, D. J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., et al. (2006). Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 135(5), 688-692. (Pubitemid 44674080)
35. Vessella, R. L., & Corey, E. (2006). Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clinical Cancer Research, 12(20 Pt 2), 6285s-6290s. (Pubitemid 44703804)
36. Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P., & Anderson, K. C. (2005). Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics, 4(4), 686-692. (Pubitemid 40601851)
37. Kane, R. C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., et al. (2007). Bortezomib for the treatment of mantle cell lymphoma. Clinical Cancer Research, 13(18 Pt 1), 5291-5294. (Pubitemid 47510352)
38. Sartor, O. (2004). Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Reviews in Urology, 6(Suppl 10), S3-S12.
39. Porter, A. T., McEwan, A. J., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., et al. (1993). Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiation Oncology Biol. Phys., 25, 805-813. (Pubitemid 23123384)
40. Baczyk, M., Czepczyński, R., Milecki, P., Pisarek, M., Oleksa, R., & Sowiński, J. (2007). 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nuclear Medicine Communications, 28(4), 245-250. (Pubitemid 46673199)
41. Bauman, G., Charette, M., Reid, R., & Sathya, J. (2005). Radiopharmaceuticals for the palliation of painful bone metastases - a systematic review. Radiotherapy and Oncology, 75(3), 258. E1-258.E13.
42. Akerley, W., Butera, J., Wehbe, T., Noto, R., Stein, B., Safran, H., et al. (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-1660. (Pubitemid 34241101)
43. Tu, S. M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet, 357, 336-341. (Pubitemid 32128538)
44. Harrison, M. R., Wong, T. Z., Armstrong, A. J., & George, D. J. (2013). Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research, 5, 1-14.
45. Rao, K. V. (2007). Lenalidomide in the treatment of multiple myeloma. American Journal of Health-System Pharmacy, 64(17), 1799-1807.
46. Murakami, H., Handa, H., Abe, M., Iida, S., Ishii, A., Ishikawa, T., et al. (2007). Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European Journal of Haematology, 79(3), 234-239. (Pubitemid 47231170)
47. Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23(5), 1011-1027. (Pubitemid 46202320)
48. Chinot, O. L. (2012). Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Expert Review of Anticancer Therapy, 12(11), 1413-1427.
49. Flaherty, K. T. (2007). Sorafenib: delivering a targeted drug to the right targets. Expert Review of Anticancer Therapy, 7(5), 617-626.
50. Pantuck, A. J., Zomorodian, N., & Belldegrun, A. S. (2006). Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Clinical Cancer Research, 12, 4018-4026.
51. Drevs, J., Zirrgiebel, U., Schmidt-Gersbach, C. I. M., Mross, K., Medinger, M., Lee, L., et al. (2005). Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer fromtwo phase I trials. Annals of Oncology, 16(4), 558-565. (Pubitemid 40613321)
52. Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., et al. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412-419.
53. Eskens, F. A. L. M., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., et al. (2003). Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. European Journal of Cancer, 39(7), 917-926. (Pubitemid 36428623)
54. Mullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., et al. (2007). Phase I evaluation of a fully human anti-alphav integrinmonoclonal antibody (CNTO95) in patients with advanced solid tumors. Clinical Cancer Research, 13(7), 2128-2135. (Pubitemid 46649882)
55. Tucker, G. C. (2006). Integrins: molecular targets in cancer therapy. Current Oncology Reports, 8(2), 96-103.
56. Gramoun, A., Shorey, S., Bashutski, J. D., Dixon, S. J., Sims, S. M., Heersche, J. N.M., et al. (2007). Effects of vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. Journal of Cellular Biochemistry, 102(2), 341-352. (Pubitemid 47519408)
57. Mulgrew, K., Kinneer, K., Yao, X.-T., Ward, B. K., Damschroder, M. M., Walsh, B., et al. (2006). Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Molecular Cancer Therapeutics, 5(12), 3122-3129. (Pubitemid 46092054)
58. Cheever, M. A., & Higano, C. S. (2011). PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical Cancer Research, 17(11), 3520-3526.
59. Kantoff, P.W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411-422.
60. So-Rosillo, R., & Small, E. J. (2006). Sipuleucel-T (APC8015) for prostate cancer. Expert Review of Anticancer Therapy, 6(9), 1163-1167. (Pubitemid 44575570)
61. Park, J.W., Melisko, M. E., Esserman, L. J., Jones, L.A., Wollan, J.B., & Sims, R. (2007). Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. Journal of Clinical Oncology, 25(24), 3680-3687. (Pubitemid 47372607)
62. de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008). Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy, 57(10), 1569-1577.
63. Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., et al. (2010). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28(7), 1099-1105.
64. Dayyani, F., Gallick, G. E., Logothetis, C. J., & Corn, P. G. (2011). Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute, 103(22), 1665-1675.
65. Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al. (2013). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology, 24(1), 75-83.
66. Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet Oncology, 13(5), 459-465.
67. Sun, J., Schiffman, J., Raghunath, A., Ng Tang, D., Chen, H., & Sharma, P. (2008). Concurrent decrease in IL-10with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immunity, 8, 9-15.
68. Fulton, A., Miller, F., Weise, A., & Wei, W.-Z. (2007). Prospects of controlling breast cancer metastasis by immune intervention. Breast Disease, 26, 115-127.
69. Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013). Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(5), 997-1008.
70. Fishelson, Z., Donin, N., Zell, S., Schultz, S., & Kirschfink, M. (2003). Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Molecular Immunology, 40, 109-123. (Pubitemid 36959821)
71. Pritchard-Jones, K., Spendlove, I., Wilton, C., Whelan, J., Weeden, S., Lewis, I., et al. (2005). Immune responses to the 105 AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. British Journal of Cancer, 92(8), 1358-1365. (Pubitemid 40705000)
72. Liao, Y., Schaue, D., & McBride, W. (2007). Modification of the tumor microenvironment to enhance immunity. Frontiers in Bioscience, 12, 3576-3600.
73. Dirkx, A. E. M., Oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A.W. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183-1196. (Pubitemid 44904956)
74. Lewis, C. E.,& Pollard, J.W. (2006). Distinct role ofmacrophages in different tumor microenvironments. Cancer Research, 66(2), 605-612. (Pubitemid 43165918)
75. Bingle, L., Brown, N. J., & Lewis, C. E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology, 196, 254-265. (Pubitemid 34189413)
76. Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European Journal of Cancer, 42(6), 717-727.
77. Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Reviews, 25(3), 315-322. (Pubitemid 44922352)
78. Porta, C., Kumar, B. S., Larghi, P., Rubino, L., Mancino, A., & Sica, A. (2007). Tumor promotion by tumor-associated macrophages. Advances in Experimental Medicine and Biology, 604, 67-86.
79. Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9(7), 556-562. (Pubitemid 47121829)
80. Bailey, C., Negus, R., Morris, A., Ziprin, P., Goldin, R., Allavena, P., et al. (2007). Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clinical & Experimental Metastasis, 24(2), 121-130. (Pubitemid 46669245)
81. Craig, M. J., & Loberg, R. D. (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Reviews, 25(4), 611-619. (Pubitemid 46071867)
82. Pienta, K. J., Machiels, J.-P., Schrijvers D., Alekseev B., M. Shkolnik, & Crabb, S. J., et al. (2013). Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs, 31(3), 760-768.
83. Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., et al. (2013). A first-in-human, firstin- class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 71(4), 1041-1050.
84. Baay, M., Brouwer, A., Pauwels, P., Peeters, M., & Lardon, F. (2011). Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy. Clinical & Developmental Immunology, p. 565187.
85. Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., et al. (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology, 3(7), 687-694. (Pubitemid 34752479)
86. Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. Journal of Clinical Investigation, 121(4), 1298-1312.
87. Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., Piwnica-Worms, D., et al. (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Research, 64(23), 8604-8612. (Pubitemid 39552073)
88. Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008). The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research, 14(9), 2519-2526.
89. Vincent, T., & Mechti, N. (2005). Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leukemia & Lymphoma, 46(6), 803-811. (Pubitemid 40959669)
90. Camacho, D. F., & Pienta, K. J. (2012). Disrupting the networks of cancer. Clinical Cancer Research, 18(10), 2801-2808.
91. Chen, K. W., & Pienta, K. J. (2011). Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. Theoretical Biology and Medical Modeling, 8(36), 1-11.